WASHINGTON, DC - The Energy and Commerce Committee, chaired by Rep. Greg Walden (R-OR), has scheduled a full committee markup on Wednesday, June 7, 2017, at 10 a.m. in room 2123 of the Rayburn House Office Building to consider H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, as well as additional legislation.
In April, bipartisan leaders of the Energy and Commerce Committee, along with bipartisan leaders of the Senate Health, Education, Labor and Pensions (HELP) Committee, released a discussion draft of the Food and Drug Administration (FDA) Reauthorization Act of 2017, reauthorizing FDA’s user fee agreements. The draft followed hearings examining the Generic Drug User Fee Amendments (GDUFA) and the Biosimilar User Fee Act (BsUFA), the Prescription Drug User Fee Act (PDUFA), and the Medical Device User Fee Amendments (MDUFA).
#SubHealth favorably reported H.R. 2430, as amended, on May 18, 2017, by voice vote.
“From the patients desperately awaiting new treatments and cures to the countless employees working in these vital health care sectors, time is of the essence as we seek to advance FDARA," said Chairman Walden. “In addition to this critically important bill, we’ll also examine some important public health initiatives that can have an important effect in our communities."
The #FullCmte will also markup two public health bills that passed by voice vote in the #SubHealth markup in May, and one additional bill:
* H.R. 1222, the Congenital Heart Futures Reauthorization Act of 2017, authored by Rep. Gus Bilirakis (R-FL) would enhance research and surveillance at the CDC, award grants to further study Congenital Heart Disease, and direct the NIH to report on their ongoing research efforts.
* H.R. 2410, the Sickle Cell Disease Research, Surveillance, prevention and Treatment Act of 2017, authored by Rep. Danny Davis (D-IL) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX), would reauthorize the sickle cell disease prevention and treatment demonstration program.
* H.R. 1492, the Medical Controlled Substances Transportation Act of 2017, authored by Rep. Pete Sessions (R-TX), is a revised version of H.R. 3014 in the 114th Congress, which passed by voice vote out of the committee. H.R. 1492 would update the Drug Enforcement Administration registration process for mobile medical practitioners like EMS personnel and team physicians to ensure these health care providers can administer controlled substances at locations other than their principal places of business while complying with new limitations on the timing of transport and related recordkeeping requirements.
The #FullCmte will also consider 11 bills related to promoting energy infrastructure and improving energy efficiency, which originated from #SubEnergy.
Electronic copies of the legislation and a background memo can be found on the Energy and Commerce Committee’s website here. Amendment text and votes will be available at the same link as they are posted. See Also
* Energy and Commerce Committee Vote on H.R. 338, H.R. 627, H.R. 723, H.R. 1109, H.R. 446, H.R. 447, H.R. 951, H.R. 2122, H.R. 2274, H.R. 2292, H.R. 2457, H.R. 1222, H.R. 2410, H.R. 2430, and H.R. 1492
